Literature DB >> 18187670

Correction of bleeding symptoms in von Willebrand factor-deficient mice by liver-expressed von Willebrand factor mutants.

Isabelle Marx1, Peter J Lenting, Thure Adler, Ronan Pendu, Olivier D Christophe, Cécile V Denis.   

Abstract

OBJECTIVE: von Willebrand Factor (vWF) structure-function relationship has been studied only in vitro. To investigate the physiological importance of particular vWF domains, we have introduced mutations into murine vWF (mvWF) cDNA inhibiting vWF binding to glycoprotein (Gp) Ib, GpIIbIIIa, and to fibrillar collagen. METHODS AND
RESULTS: We delivered wild-type (WT) or mutant mvWF cDNA into vWF-deficient (Vwf-/-) mice using hydrodynamic injection and assessed whether hemorrhagic symptoms could be corrected. Hydrodynamic gene transfer resulted in high expression of plasma mvWF 24 hours after injection (438+/-63% for 50 microg of cDNA). Factor VIII activity was normalized in Vwf-/- mice injected with mvWF cDNA and multimerization was achieved. Bleeding time was corrected after injection of WT mvWF cDNA in Vwf-/- mice whereas noninjected mice did not stop bleeding. Injection of the GpIIbIIIa and the collagen binding mutants in Vwf-/- mice also resulted in a correction of bleeding time whereas mice injected with the GpIb binding mutant were bleeding for as long they were observed, although blood loss was decreased compared with noninjected mice (61+/-21 microL versus 232+/-63 microL).
CONCLUSIONS: Our model allows the rapid in vivo evaluation of specific mutations on plasma vWF function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18187670     DOI: 10.1161/ATVBAHA.107.159442

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  14 in total

1.  Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis.

Authors:  S Kanaji; S A Fahs; Q Shi; S L Haberichter; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

2.  Gene Therapy for Inherited Bleeding Disorders.

Authors:  Valder R Arruda; Jesse Weber; Benjamin J Samelson-Jones
Journal:  Semin Thromb Hemost       Date:  2021-02-26       Impact factor: 4.180

3.  In vivo gene transfer strategies to achieve partial correction of von Willebrand disease.

Authors:  Lan Wang; Jonathan B Rosenberg; Bishnu P De; Barbara Ferris; Rui Wang; Stefano Rivella; Stephen M Kaminsky; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2012-06-25       Impact factor: 5.695

4.  Humanized GPIbα-von Willebrand factor interaction in the mouse.

Authors:  Sachiko Kanaji; Jennifer N Orje; Taisuke Kanaji; Yuichi Kamikubo; Yosuke Morodomi; Yunfeng Chen; Alessandro Zarpellon; Jerome Eberhardt; Stefano Forli; Scot A Fahs; Rashmi Sood; Sandra L Haberichter; Robert R Montgomery; Zaverio M Ruggeri
Journal:  Blood Adv       Date:  2018-10-09

5.  Analysis of the role of von Willebrand factor, platelet glycoprotein VI-, and α2β1-mediated collagen binding in thrombus formation.

Authors:  Yasuaki Shida; Natalia Rydz; David Stegner; Christine Brown; Jeffrey Mewburn; Kate Sponagle; Ozge Danisment; Bredon Crawford; Barbara Vidal; Carol A Hegadorn; Cynthia M Pruss; Bernhard Nieswandt; David Lillicrap
Journal:  Blood       Date:  2014-07-22       Impact factor: 22.113

6.  Blocking von Willebrand factor for treatment of cutaneous inflammation.

Authors:  Carina Hillgruber; Annika K Steingräber; Birgit Pöppelmann; Cécile V Denis; Jerry Ware; Dietmar Vestweber; Bernhard Nieswandt; Stefan W Schneider; Tobias Goerge
Journal:  J Invest Dermatol       Date:  2013-06-28       Impact factor: 8.551

7.  In vivo analysis of the role of O-glycosylations of von Willebrand factor.

Authors:  Idinath Badirou; Mohamad Kurdi; Paulette Legendre; Julie Rayes; Marijke Bryckaert; Caterina Casari; Peter J Lenting; Olivier D Christophe; Cecile V Denis
Journal:  PLoS One       Date:  2012-05-17       Impact factor: 3.240

Review 8.  Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis.

Authors:  Marcus Stockschlaeder; Reinhard Schneppenheim; Ulrich Budde
Journal:  Blood Coagul Fibrinolysis       Date:  2014-04       Impact factor: 1.276

9.  On the versatility of von Willebrand factor.

Authors:  Antoine Rauch; Nikolett Wohner; Olivier D Christophe; Cécile V Denis; Sophie Susen; Peter J Lenting
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-07-10       Impact factor: 2.576

10.  Von Willebrand Factor Abnormalities Studied in the Mouse Model: What We Learned about VWF Functions.

Authors:  Caterina Casari; Peter J Lenting; Olivier D Christophe; Cécile V Denis
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-07-10       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.